Provider review
Synergy Rx Review: Five Peptides at One Price, and a Headline It Cannot Support
Synergy Rx prices almost its entire longevity range identically: NAD+, sermorelin, glutathione and PT-141 are each "Starting at $275", with B12 at $109. Four molecules with four completely different evidence bases, four different manufacturing considerations and four different reasons to be taken, all at one number. Its homepage headline is "The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week" — the word proven, the STEP 1 figure, and a rate of loss, with no citation anywhere on the site. It does one thing genuinely well: its FAQ names four dispensing pharmacies with phone numbers and websites, and two prescribing doctors with NPI numbers. Its Terms, meanwhile, are substantially a different company's document — CareGLP appears 68 times, SynergyRx 56 — name no pharmacy at all, and contain not one instance of the words subscription or cancel.
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens synergyrx.co. A link is not a recommendation to take anything.
Provenance
What Synergy Rx actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin Injection — "Starting at $275" — a floor, not a price. Synergy publishes no dose, no supply length and no billing interval.
- NAD+ Injection — "Starting at $275" — identical to sermorelin, glutathione and PT-141.
- Glutathione Injection — "Starting at $275".
- PT-141 — "Starting at $275".
- Compounded semaglutide — $199 — read in-browser on 2026-08-10 from the WEIGHT LOSS tab of `/products`. ⚠ A static fetch of that page returns the LONGEVITY tab instead, which is why an earlier pass wrongly concluded no GLP-1 price was published.
- Compounded tirzepatide — $349, and oral semaglutide $299 — both read in-browser on 2026-08-10 from the WEIGHT LOSS tab.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
4
Products with a human trial
Out of 6 reviewed here.
6
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Synergy Rx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Sermorelin InjectionSermorelin · Compounded (503A)No trial supports this claim
“Sermorelin Injection — Starting at $275. […] Find the right medication with the confidence that comes from knowing it is doctor-approved and budget-friendly. […] Certified Medication.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns NO interventional record naming sermorelin as the intervention, in any phase and at any status. Six query forms were run — intervention "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and "Geref", its withdrawn brand name — plus a free-text search of every field. The 27 studies returned are all different molecules: tesamorelin (TH9507/Egrifta), GHRH(1-44), or unspecified diagnostic "GHRH". In PubMed, "sermorelin" appears in 24 titles or abstracts and ZERO carry the randomised-controlled-trial or clinical-trial publication type. The searches discriminate: in the same pass tirzepatide returned 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
Synergy publishes no description of sermorelin at all — no mechanism, no indication, no benefit, no contraindication — so there is no sentence to hold against the literature, and no trial to hold it against either: no registered study names sermorelin as an intervention under any of six query forms. What the site does assert, across the whole range, is that its medication is "doctor-approved" and "Certified" — neither of which is a term with a meaning a reader can check. ⚠ Note the pricing: sermorelin is $275, exactly the same as NAD+, glutathione and PT-141, three molecules with completely different evidence bases and manufacturing profiles.1,2
NAD+ InjectionNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“NAD+ Injection — Starting at $275. […] Trusted by experts, priced for you. Find the right medication with the confidence that comes from knowing it is doctor-approved and budget-friendly.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search for injected NAD+ in humans returns no completed randomised trial supporting a restoration-of-function claim, and a PubMed search for "nicotinamide adenine dinucleotide" combined with injection or subcutaneous, filtered to the randomised-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
As with sermorelin, no description is published — the product exists as a name, a price and a "Get Started" button. Injected NAD+ has no completed randomised human trial behind it. The only assertions attached are "Trusted by experts" and "doctor-approved", which name no expert and describe no approval that exists: FDA approves no compounded preparation, and a prescriber's willingness to write a prescription is not an approval of a product.3
Glutathione InjectionGlutathione · Compounded (503A)No trial supports this claim
“Glutathione Injection — Starting at $275. […] doctor-approved and budget-friendly.”
Phase 1 only
- NCT01355198 — Phase 1, completed, n=10. Ten participants, on glutathione synthesis and oxidative stress in HIV infection.
- NCT02348775 — Phase 1, completed, n=16. Sixteen participants, glutathione and function in HIV patients. Together these are effectively the whole injected-glutathione human record in adults.
The entire human record for injected glutathione in adults is two phase 1 studies enrolling ten and sixteen people, both about oxidative stress in HIV infection. A ClinicalTrials.gov search returning 200 glutathione intervention records yields only four involving an injected or intravenous route, the other two being a neonatal cysteine-supplementation study and a lymphoma chemotherapy trial. Synergy states no indication, so there is no claim to check — and nothing in that literature supports a wellness or longevity purchase at $275.4
PT-141Bremelanotide (PT-141) · Compounded (503A)No trial supports this claim
“PT-141 — Starting at $275. […] Sexual Health. […] doctor-approved and budget-friendly.”
Phase 3 trials
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Bremelanotide in premenopausal women with hypoactive sexual desire disorder. No male participants.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The second registration trial, same population. The resulting approval is for premenopausal women only.
PT-141 is bremelanotide, and it is the one molecule in Synergy's longevity range with phase 3 evidence — 723 and 714 participants, all premenopausal women with hypoactive sexual desire disorder. The approved product containing it is Vyleesi, whose label carries two consecutive Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men" and "VYLEESI is not indicated to enhance sexual performance." Synergy lists PT-141 under Sexual Health with no indication, no population and no mention of either limitation, at the same $275 as three unrelated molecules. There is real evidence here; it is for a population and a purpose the product page does not identify.5,6
Compounded semaglutideSemaglutide · Compounded (503A)Claim reaches past the trials
“The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized. […] Join 50,000+ SynergyRx patients.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved 2.4 mg product over 68 weeks; about 14.9% weight loss from baseline against 2.4% on placebo. No compounded semaglutide from any seller has been through a registered trial.
Four words do the damage. "PROVEN" — Synergy cites nothing, anywhere on the site, and what it dispenses is a compounded preparation that has never been in a registered trial. "15%" is STEP 1's figure, borrowed without attribution and attached to Synergy's own service. "FAST" is the opposite of what STEP 1 describes: that result took 68 weeks. And "EFFORTLESS" is contradicted by the trial itself, in which every participant received structured lifestyle intervention alongside the drug. "Lose 1-2lbs per week" is a rate claim with nothing behind it. The molecule genuinely works — that is not in question — but every qualifier attached to it here is wrong in the direction that flatters the sale.7
Compounded tirzepatideTirzepatide · Compounded (503A)Claim reaches past the trials
“The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week. […] Medically supervised, effortless weight loss that's personalized.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved product at the highest tolerated dose over 72 weeks.
The same site-wide headline covers tirzepatide, and it fits even less well: the 15% figure belongs to semaglutide's STEP 1, while SURMOUNT-1 reported roughly 20% for tirzepatide over 72 weeks. So the headline simultaneously under-describes one molecule and over-qualifies both, with "proven", "fast" and "effortless" attached to results that took a year and a half under trial conditions. Synergy makes no molecule-specific claim for tirzepatide anywhere.8
Dispensing chain
Who actually fills your prescription
- Belmar Pharmacy
- Strive Pharmacy
- Epiq Scripts
- Casa Pharma Rx
Read the full account
Synergy names four dispensing pharmacies with phone numbers and websites in its homepage FAQ — "Belmar Pharmacy | Phone: 800-525-9473 | belmarpharmasolutions.com; Strive Pharmacy | Phone: 855-405-5993 | strivepharmacy.com; Epiq Scripts | Phone: 833-654-3553 | epiqscripts.com; Casa Pharma Rx | Phone: 877-937-6868 | casapharmarx.com" — and two prescribing clinicians with NPI numbers: Dr. Ana Lisa Carr MD (1689841744) and Dr. Kelly Tenbrink MD (1346482684), both through Lion MD. That is a real, checkable disclosure and it is the best thing on this site. ⛔ IT EXISTS IN ONE DOCUMENT ONLY. Synergy's Terms & Conditions name no pharmacy at all, so a reviewer who reads the Terms — the natural place to look — concludes that this company names none, which is false. That failure is recorded here because it is the kind that corrupts a structured field and every board row derived from it. ⚠ Which of the four fills a given order is not disclosed. ⚠ Belmar's own FDA letter of 31 March 2023 was CLOSED OUT on 30 October 2023, belongs to the pharmacy rather than to Synergy, and is filed nowhere. ⚠ Synergy shares a backend with another brand in this wave — an identical live Stripe key, the same Supabase project and the same CareValidate endpoint, with distinct organisation IDs and seals. ⛔ COMMON OWNERSHIP IS NOT PROVEN and is not asserted; a shared white-label platform is not grounds to treat the brands as duplicates.
Read on August 2026 from https://synergyrx.co/
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup is published for any product. The quality vocabulary is a list of adjectives that cannot be checked: "Certified Medication", "doctor-approved", "Trusted by experts", "Licensed Providers". None of those is a standard, and "doctor-approved" in particular describes a prescriber's willingness to write a prescription rather than any approval of a product — FDA approves no compounded preparation. ⚠ What Synergy does publish, and what genuinely helps, is the pharmacy list: four named facilities with phone numbers, which at least gives a patient somebody to ask for a lot record. ⚠ No study, trial identifier or publication is cited anywhere on the site, for any product — including for the two GLP-1 molecules whose phase 3 programmes its own headline is borrowing a number from.
Read on August 2026 from https://synergyrx.co/
Licensing
Licensed to dispense, and where
Coverage
"All 50 U.S. states" by the FAQ; "certain states" by the Terms, with no list published
Read the full licensing claim
Synergy's two published answers do not agree. Its homepage FAQ: "Is this service available in all states? Our telemedicine services are available in all 50 U.S. states, subject to each state's telehealth and prescribing regulations." Its Terms, section V: "The Services are currently available to individuals located in certain states. To see the list of current states, please contact customer service at info@synergyrx.co." No list is published anywhere, so `statesExcluded` is empty because naming exclusions would mean inventing them, not because none exist. ⚠ The corporate structure is unusual and worth reading in full: "The terms 'we', 'us', 'our' and 'CareGLP' refer to CareGLP, owned by SynergyRx, a Delaware corporation located at 5830 E 2nd St, Ste 7000 #2603, Casper, WY 82609" — a Delaware corporation at a Wyoming address — with disputes to be resolved "exclusively in the U.S. District Court for Georgia, or a state court located in Fulton County, Georgia". Three states for one company, and the operating brand named in the agreement is a different one from the one on the storefront. ⚠ The Terms are dated "Last updated: January 1, 2024" and contain ZERO occurrences of "subscription" and ZERO of "cancel", so a patient buying a recurring medication has no published cancellation terms at all.
Read on August 2026 from https://synergyrx.co/terms
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Its FAQ names four dispensing pharmacies with phone numbers and working websites — Belmar, Strive, Epiq Scripts and Casa Pharma Rx.
- Two prescribing clinicians are named with NPI numbers, Dr. Ana Lisa Carr (1689841744) and Dr. Kelly Tenbrink (1346482684), both verifiable in the federal NPPES registry.
- Peptide prices are server-rendered and visible without an intake — five products with figures on the page, which several competitors will not do before collecting a phone number.
Show 3 more
- The eligibility criteria are stated concretely: "A BMI of 30 or higher, or a BMI of 27+ with at least one weight-related condition", which matches the criteria the trials used.
- It acknowledges that its GLP-1s are compounded formulations "through licensed U.S. compounding pharmacies that comply with FDA and state regulations" rather than implying they are the branded drug.
- No FDA warning letter — screened against the live index on both SynergyRx and CareGLP with a positive control that fired.
- "The Proven Way to lose 15% of your body weight fast!" — nothing is cited anywhere on the site, and the 15% belongs to STEP 1, a 68-week trial of the approved product.
- "Fast" and "effortless" both contradict that trial, which took 68 weeks and gave every participant structured lifestyle support alongside the drug.
- "Lose 1-2lbs per week" is a rate-of-loss claim with no source.
Show 10 more
- Four unrelated molecules — sermorelin, NAD+, glutathione and PT-141 — are all priced at exactly $275, and all five longevity products are "Starting at" floors with no dose, supply length or billing interval published.
- No description is published for any peptide: no mechanism, indication, benefit or contraindication for sermorelin, NAD+, glutathione or PT-141.
- PT-141 is sold under Sexual Health with no indication stated, when the approved product's label says it is not indicated in men and not indicated to enhance sexual performance.
- The Terms name no pharmacy, so the disclosure exists in exactly one document and the natural place to look contradicts it by silence.
- The Terms are substantially another brand's: "CareGLP" appears 68 times against 56 for "SynergyRx", and the agreement opens by describing CareGLP's scope rather than Synergy's.
- They contain zero occurrences of "subscription" and zero of "cancel" — no published cancellation terms for a recurring medication.
- "Available in all 50 U.S. states" in the FAQ against "available to individuals located in certain states" in the Terms, with no list published in either.
- Three jurisdictions for one company: a Delaware corporation, at a Wyoming address, with disputes venued in Fulton County, Georgia.
- Weight-loss prices are behind a client-rendered tab that defaults to Longevity, so a reader — or a tool — can look at the products page and never see them.
- No certificate of analysis, lot number or laboratory result is published, and no study is cited anywhere for any product.
Verdict
The bottom line
Synergy Rx has one genuinely good disclosure and builds nothing on top of it. Its FAQ names four pharmacies with phone numbers and two doctors with checkable NPIs — and then its Terms, the document a careful reader would actually open, name no pharmacy, belong substantially to a different company, and contain not one occurrence of the words subscription or cancel. Its longevity range prices four unrelated molecules at exactly $275 with no description of any of them: sermorelin, which has no trial record at all; injected glutathione, whose entire human record is twenty-six people with HIV; injected NAD+, which has no completed trial; and PT-141, which has real phase 3 evidence in premenopausal women and an approved label stating it is not indicated in men. Over all of it sits a headline promising "The Proven Way to lose 15% of your body weight fast" — proven by nothing the site cites, 15% borrowed from a 68-week trial of a different product, and fast being the one thing that trial specifically was not.
Opens synergyrx.co. A link is not a recommendation to take anything.
The tab that made this site's rule
Before anything else, a correction this network published against itself.
An earlier research pass on Synergy Rx — and a plain `curl` of its products page — both concluded that no GLP-1 price was published anywhere, and that the catalogue was unreachable JavaScript. That was wrong.
Synergy's `/products` page has category tabs: LONGEVITY, HAIR, SEXUAL HEALTH, SKIN, WEIGHT LOSS. It opens on Longevity. One click on Weight Loss renders semaglutide at $199, tirzepatide at $349 and oral semaglutide at $299.
What makes the mistake instructive is the detail confirmed again today. The served HTML does contain real prices — the five Longevity products, complete with figures. A static fetch therefore does not look empty or broken. It looks like a working page with a complete product list, and that list simply does not include the GLP-1s. There is nothing to alert a careless reader that four more tabs exist.
A client-rendered tab is not an unreachable price. Every peptide figure below was read from the served HTML; the GLP-1 figures are the in-browser ones and are labelled as such.
Full analysis — 5 more sectionsFour molecules, one price · What the registries hold for those four · "The Proven Way to lose 15% of your body weight fast!" · Two documents, two companies, three states · What this means if you are buying
Four molecules, one price
Synergy's longevity range, as its own page renders it:
| Product | Price | |---|---| | NAD+ Injection | Starting at $275 | | Sermorelin Injection | Starting at $275 | | Glutathione Injection | Starting at $275 | | PT-141 | Starting at $275 | | B12 Methylcobalamin | Starting at $109 |
Four different molecules at an identical price. They have nothing in common. Sermorelin is a growth-hormone-releasing peptide. NAD+ is a coenzyme. Glutathione is a tripeptide antioxidant. PT-141 is a melanocortin receptor agonist for sexual desire. Their evidence bases, their manufacturing considerations and their reasons for being taken are entirely unrelated, and they cost the same.
Every one is "Starting at", which is a floor rather than a price, and Synergy publishes no dose, no supply length and no billing interval for any of them.
It also publishes no description of any of them. There is no mechanism, no indication, no benefit, no contraindication, no side-effect list. Each product is a name, a number and a "Get Started" button. The only claims attached are site-wide adjectives: "doctor-approved", "Certified Medication", "Trusted by experts".
"Doctor-approved" is worth pausing on. It describes a prescriber's willingness to write a prescription. It is not an approval of a product, and FDA approves no compounded preparation at all.
What the registries hold for those four
Sermorelin has nothing. A ClinicalTrials.gov search returns no interventional record naming it as the intervention, across six query forms including "sermorelin acetate", "GHRH(1-29)" and "Geref", its withdrawn US brand name, plus a free-text pass over every field. 1 The 27 studies returned are other molecules — mostly tesamorelin and GHRH(1-44). PubMed holds 24 records mentioning it and none with a randomised-trial publication type. 2 Controls run in the same pass: tirzepatide 158 registry records and 126 papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
Injected NAD+ has no completed randomised human trial supporting a restoration-of-function claim. 3 The real literature is about oral precursors — different molecules, different route.
Injected glutathione has almost nothing: of 200 glutathione intervention records, four involve an injected or intravenous route, and the two studying it in adults are phase 1 trials of ten and sixteen people, both about oxidative stress in HIV infection. 4
PT-141 is the interesting one, because it has the most evidence and the widest gap. Bremelanotide has two phase 3 trials, RECONNECT 1 and 2, enrolling 723 and 714 participants — all premenopausal women with hypoactive sexual desire disorder. 5 6 The approved product is Vyleesi, and its label carries two consecutive Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance."
Synergy lists PT-141 under "Sexual Health" with no indication, no population and no mention of either sentence.
"The Proven Way to lose 15% of your body weight fast!"
That is Synergy's homepage headline, beneath "Medically supervised, effortless weight loss that's personalized" and above "Lose 1-2lbs per week."
Four words in it are doing work the site cannot support.
"Proven." Synergy cites nothing. Not a trial, not a PubMed ID, not a study name — anywhere on the site, for any product. And what it dispenses is a compounded preparation, which has never been through a registered trial from any seller.
"15%." That is STEP 1's number: roughly 14.9% weight loss from baseline against 2.4% on placebo. 7 It is real, and it belongs to the approved 2.4 mg product, not to Synergy's compounded version. It is borrowed without attribution and attached to Synergy's own service.
"Fast." STEP 1 took 68 weeks to produce that result. Sixteen months is not fast, and describing it that way inverts the single most important expectation a patient should start with.
"Effortless." In STEP 1, every participant — treatment and placebo alike — received structured lifestyle intervention: a reduced-calorie diet and increased physical activity, with monthly counselling. The 15% figure is what the drug added on top of that effort. "Effortless" describes the one condition under which the number was not obtained.
"Lose 1-2lbs per week" is a rate claim with no source at all.
The underlying molecules work. Semaglutide and tirzepatide have large, genuine phase 3 programmes. 7 8 Every qualifier Synergy attaches to them points in the direction that flatters the sale.
Two documents, two companies, three states
Synergy's FAQ does the best thing on the site:
"Who are your Pharmacy Providers? … Belmar Pharmacy | 800-525-9473 | belmarpharmasolutions.com · Strive Pharmacy | 855-405-5993 · Epiq Scripts | 833-654-3553 · Casa Pharma Rx | 877-937-6868"
Plus two named doctors with NPI numbers you can look up. That is a real disclosure.
Now open the Terms & Conditions — the document a careful buyer would actually read. It names no pharmacy at all. Anyone who checks there concludes this company discloses nothing, which is false. The disclosure exists in exactly one place, and it is not the place with legal force.
The Terms have other problems. They open:
"CAREGLP IS CONTEMPLATED FOR SPECIFIC NON-EMERGENCY MEDICAL CONDITIONS AND CONCERNS."
"CareGLP" appears 68 times in that document; "SynergyRx" appears 56. The agreement is substantially another brand's, lightly adapted. It defines the parties as "CareGLP, owned by SynergyRx, a Delaware corporation located at 5830 E 2nd St, Ste 7000 #2603, Casper, WY 82609", and venues disputes "exclusively in the U.S. District Court for Georgia, or a state court located in Fulton County, Georgia."
A Delaware corporation, at a Wyoming address, litigating in Georgia.
The document is dated 1 January 2024 and contains zero occurrences of "subscription" and zero of "cancel". A patient buying a recurring medication has no published cancellation terms.
And on coverage, the two documents disagree outright. The FAQ: "Our telemedicine services are available in all 50 U.S. states." The Terms, section V: "The Services are currently available to individuals located in certain states. To see the list of current states, please contact customer service." Neither publishes a list.
What this means if you are buying
The pharmacy list is real and useful: four named facilities with phone numbers, and two doctors whose NPIs you can verify. If you buy here, use it — ring the pharmacy and ask for the lot record, because Synergy publishes no certificate of analysis for anything.
On the GLP-1s, the medicine is well evidenced and the headline is not. Expect a 68-week horizon and lifestyle work, not "fast" and "effortless". The prices — $199 semaglutide, $349 tirzepatide, $299 oral — are behind the Weight Loss tab, which the page does not open on.
On the four $275 products, there is no description to read, and the evidence runs from "two phase 1 studies in twenty-six people" to "nothing at all". PT-141 is the one with real trials behind it, and those trials were in women, for a condition Synergy does not name.
Before you commit to anything recurring, note that the Terms do not contain the word cancel.
Questions
Frequently asked questions
Does Synergy Rx publish its GLP-1 prices?
Yes — behind a tab that the page does not open on, which is why an earlier check of this company got it wrong. Synergy's /products page has category tabs (Longevity, Hair, Sexual Health, Skin, Weight Loss) and defaults to Longevity. One click on Weight Loss renders semaglutide $199, tirzepatide $349 and oral semaglutide $299, re-verified in a browser on 10 August 2026. What makes this an easy mistake is that the served HTML is not empty: it contains the five Longevity products with real prices, so a static fetch looks like a complete, working product page that simply has no GLP-1s on it. A client-rendered tab is not an unreachable price.
Why are four different peptides all $275?
Synergy does not say. NAD+ Injection, Sermorelin Injection, Glutathione Injection and PT-141 are each listed "Starting at $275", with B12 at $109. Those four molecules have nothing in common — a growth-hormone-releasing peptide, a coenzyme, a tripeptide antioxidant and a melanocortin receptor agonist — and their evidence bases range from two phase 1 studies to none at all. Every figure is a "Starting at" floor rather than a price, and Synergy publishes no dose, no supply length and no billing interval for any of them. It also publishes no description of any of them: no mechanism, no indication, no benefit, no contraindication.
Is Synergy Rx's "15% weight loss" claim accurate?
The number is real and everything around it is wrong. Synergy's homepage reads "The Proven Way to lose 15% of your body weight fast! Lose 1-2lbs per week", under "effortless weight loss". The 15% comes from STEP 1, which reported about 14.9% from baseline against 2.4% on placebo — but that trial tested the approved 2.4 mg product, not a compounded preparation, and Synergy cites nothing anywhere on its site. "Fast" is the opposite of the truth: STEP 1 ran 68 weeks. "Effortless" is contradicted by the trial's design, in which every participant received a reduced-calorie diet, increased activity and monthly counselling — the 15% is what the drug added on top of that effort. "Lose 1-2lbs per week" has no source at all.
Which pharmacy does Synergy Rx use?
It names four in its homepage FAQ, with phone numbers and websites: Belmar Pharmacy (800-525-9473), Strive Pharmacy (855-405-5993), Epiq Scripts (833-654-3553) and Casa Pharma Rx (877-937-6868). It also names two prescribing clinicians with NPI numbers — Dr. Ana Lisa Carr MD (1689841744) and Dr. Kelly Tenbrink MD (1346482684) — through Lion MD. That is a genuine disclosure and the best thing on the site. The catch is that it exists in exactly one document: Synergy's Terms & Conditions name no pharmacy at all, so anyone who looks in the legally binding document concludes this company discloses nothing. Which of the four fills a given order is not published.
What do Synergy Rx's terms actually say?
Less about Synergy than you would expect. The agreement is substantially another brand's document: "CareGLP" appears 68 times against 56 for "SynergyRx", and it opens "CAREGLP IS CONTEMPLATED FOR SPECIFIC NON-EMERGENCY MEDICAL CONDITIONS AND CONCERNS". It defines the parties as "CareGLP, owned by SynergyRx, a Delaware corporation located at 5830 E 2nd St, Ste 7000 #2603, Casper, WY 82609" and venues disputes in Fulton County, Georgia — three states for one company. It is dated 1 January 2024. Most consequentially for a patient buying a recurring medication, it contains zero occurrences of the word "subscription" and zero of the word "cancel", so there are no published cancellation terms. Its section V also says services are available "in certain states", where the homepage FAQ says all 50.
Is PT-141 appropriate for men?
The approved label says it is not, and Synergy does not mention the question. PT-141 is bremelanotide, and its two phase 3 trials — RECONNECT 1 and 2, enrolling 723 and 714 participants — were in premenopausal women with hypoactive sexual desire disorder. The approved product containing the molecule is Vyleesi, whose label carries two consecutive Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men" and "VYLEESI is not indicated to enhance sexual performance." Synergy lists PT-141 under Sexual Health at $275 with no indication, no population and no reference to either sentence. This site does not tell you what to take; it reports that the evidence is real, and is for a different population and a different purpose than the listing implies.
Glossary
Key terms
Show definitions
- Client-rendered tab
- Page content that loads only when a user clicks a control, and is absent from the HTML the server first returns. It is published information — it is simply invisible to a fetch. Synergy's weight-loss prices sit behind one, which is how a previous check of this company concluded no price existed.
- Starting at
- A floor, not a price. It states the lowest figure in a range without committing to a dose, a supply length or a billing interval. All five of Synergy's longevity products are priced this way.
- Limitations of Use
- A section of an FDA-approved label stating what a drug is specifically not indicated for — a boundary on the approval itself rather than a caution. Vyleesi's names men, postmenopausal women and performance enhancement.
- Sermorelin
- A synthetic fragment of growth hormone-releasing hormone, GHRH(1-29). Once approved in the US as Geref; that approval has been withdrawn, and no current ClinicalTrials.gov record names sermorelin as an intervention.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Synergy Rx's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 8 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 search: no interventional record names sermorelin as the intervention. Six query forms run — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", "Geref" — plus a free-text pass. Positive controls in the same pass: tirzepatide 158 records, tesamorelin 17, bremelanotide 10. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sermorelin
- US National Library of Medicine (2026). PubMed search: "sermorelin"[tiab] returns 24 records; "sermorelin"[tiab] AND randomized controlled trial[pt] returns 0, as does the clinical trial publication type. Positive controls: tirzepatide 126, tesamorelin 21, bremelanotide 11. Run 2026-08-10.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected NAD+ in humans: no completed randomised trial supporting a restoration-of-function claim; zero randomised-controlled-trial publications for nicotinamide adenine dinucleotide combined with injection or subcutaneous administration. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- US National Library of Medicine (2026). Injected glutathione in humans — of 200 glutathione intervention records, only four involve an injected or intravenous route, and the two studying it in adults are NCT01355198 (phase 1, n=10) and NCT02348775 (phase 1, n=16), both on oxidative stress in HIV infection. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=glutathione
- US National Library of Medicine (2026). RECONNECT Study 1 (NCT02333071, phase 3, completed, n=723) and RECONNECT Study 2 (NCT02338960, phase 3, completed, n=714) — bremelanotide in premenopausal women with hypoactive sexual desire disorder. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02333071
- US Food and Drug Administration (2026). VYLEESI (bremelanotide) injection — prescribing information, section 1, Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." Read 2026-08-10.. FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.